Sebastian Ewen1, Oliver Dörr, Christian Ukena, Dominik Linz, Bodo Cremers, Ulrich Laufs, Christian Hamm, Holger Nef, Axel Bauer, Giuseppe Mancia, Michael Böhm, Felix Mahfoud. 1. aKlinik für Innere Medizin III, Kardiologie, Angiologie und Internistische Intensivmedizin Universitätsklinikum des Saarlandes, Homburg/Saar bUniversity of Giessen, Department of Cardiology, Giessen cMedizinische Klinik und Poliklinik I, Ludwig Maximilian Universität, and Deutsches Zentrum für Herzkreislaufforschung (DZHK), München, Germany dIRCCS Istituto Auxologico Italiano, University of Milano-Bicocca, Milan, Italy.
Abstract
BACKGROUND: Renal denervation (RDN) reduces sympathetic activity and blood pressure (BP) in patients with resistant hypertension. Increased 24-h BP variability is associated with adverse cardiovascular outcomes and related to sympathetic activation. METHODS AND RESULTS: This multicenter study investigated the effect of RDN on BP variability in 84 patients with uncontrolled hypertension (office systolic BP ≥140 mmHg) despite treatment with greater than three antihypertensive agents. BP variability was assessed by means of standard deviation, coefficient of variation (standard deviation/mean), and average real variability of 24-h ambulatory SBP at 3-month and 6-month follow-up. RDN significantly reduced office BP by 17/6 mmHg at 3-month and 19/7 mmHg at 6-month follow-up (P < 0.001 for all) and 24-h ambulatory BP by 9/5 mmHg (P < 0.001/P = 0.001) after 3 months and 12/7 mmHg (P < 0.001/P < 0.001) after 6 months. Standard deviation significantly decreased from 17.1 to 14.9 mmHg (P = 0.008) and 15.3 mmHg (P = 0.037), consistent with a reduction of coefficient of variation from 0.116 to 0.103 (P = 0.035) and 0.104 (P = 0.071) and average real variability from 12.3 to 10.9 (P = 0.029) and 11.0 (P = 0.054) after 3-month and 6-month, respectively. Interestingly, also BP nonresponders (change in office systolic BP < 10 mmHg after 6 months) showed a significant reduction of standard deviation after 3 months (P = 0.041, n = 26) and a borderline significant reduction at 6-month (P = 0.057, n = 28). CONCLUSIONS: RDN reduces office and ambulatory BP and BP variability in patients with resistant hypertension. Improvement in BP variability was also documented in patients characterized as office BP nonresponders after 6 months.
BACKGROUND: Renal denervation (RDN) reduces sympathetic activity and blood pressure (BP) in patients with resistant hypertension. Increased 24-h BP variability is associated with adverse cardiovascular outcomes and related to sympathetic activation. METHODS AND RESULTS: This multicenter study investigated the effect of RDN on BP variability in 84 patients with uncontrolled hypertension (office systolic BP ≥140 mmHg) despite treatment with greater than three antihypertensive agents. BP variability was assessed by means of standard deviation, coefficient of variation (standard deviation/mean), and average real variability of 24-h ambulatory SBP at 3-month and 6-month follow-up. RDN significantly reduced office BP by 17/6 mmHg at 3-month and 19/7 mmHg at 6-month follow-up (P < 0.001 for all) and 24-h ambulatory BP by 9/5 mmHg (P < 0.001/P = 0.001) after 3 months and 12/7 mmHg (P < 0.001/P < 0.001) after 6 months. Standard deviation significantly decreased from 17.1 to 14.9 mmHg (P = 0.008) and 15.3 mmHg (P = 0.037), consistent with a reduction of coefficient of variation from 0.116 to 0.103 (P = 0.035) and 0.104 (P = 0.071) and average real variability from 12.3 to 10.9 (P = 0.029) and 11.0 (P = 0.054) after 3-month and 6-month, respectively. Interestingly, also BP nonresponders (change in office systolic BP < 10 mmHg after 6 months) showed a significant reduction of standard deviation after 3 months (P = 0.041, n = 26) and a borderline significant reduction at 6-month (P = 0.057, n = 28). CONCLUSIONS: RDN reduces office and ambulatory BP and BP variability in patients with resistant hypertension. Improvement in BP variability was also documented in patients characterized as office BP nonresponders after 6 months.
Authors: Christopher T Banek; Madeline M Gauthier; Daniel C Baumann; Dusty Van Helden; Ninitha Asirvatham-Jeyaraj; Angela Panoskaltsis-Mortari; Gregory D Fink; John W Osborn Journal: Am J Physiol Regul Integr Comp Physiol Date: 2018-03-07 Impact factor: 3.619
Authors: Juan Gao; Edmund K Kerut; Frank Smart; Akemi Katsurada; Dale Seth; L Gabriel Navar; Daniel R Kapusta Journal: Am J Hypertens Date: 2016-12-01 Impact factor: 2.689
Authors: Henry Boardman; Adam J Lewandowski; Merzaka Lazdam; Yvonne Kenworthy; Polly Whitworth; Charlotte L Zwager; Jane M Francis; Christina Y L Aye; Wilby Williamson; Stefan Neubauer; Paul Leeson Journal: J Hypertens Date: 2017-03 Impact factor: 4.844
Authors: Karl Fengler; Paul Reimann; Karl-Philipp Rommel; Karl-Patrik Kresoja; Stephan Blazek; Matthias Unterhuber; Christian Besler; Maximilian von Roeder; Michael Böhm; Steffen Desch; Holger Thiele; Philipp Lurz Journal: J Am Heart Assoc Date: 2021-10-29 Impact factor: 5.501
Authors: Yann Vuignier; Eric Grouzmann; Olivier Muller; Nima Vakilzadeh; Mohamed Faouzi; Marc P Maillard; Salah D Qanadli; Michel Burnier; Grégoire Wuerzner Journal: Front Cardiovasc Med Date: 2018-05-23